Resistance to tyrosine kinase inhibitors: Calling on extra forces
- 30 June 2005
- journal article
- review article
- Published by Elsevier in Drug Resistance Updates
- Vol. 8 (3) , 119-129
- https://doi.org/10.1016/j.drup.2005.04.005
Abstract
No abstract availableKeywords
This publication has 85 references indexed in Scilit:
- Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disordersThe Lancet, 2005
- Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistanceProceedings of the National Academy of Sciences, 2005
- A Missense Mutation in KIT Kinase Domain 1 Correlates with Imatinib Resistance in Gastrointestinal Stromal TumorsCancer Research, 2004
- Stable expression of small interfering RNA sensitizes TEL-PDGFβR to inhibition with imatinib or rapamycinJournal of Clinical Investigation, 2004
- Characterization of a Conserved Structural Determinant Controlling Protein Kinase Sensitivity to Selective InhibitorsChemistry & Biology, 2004
- New cancer therapeutics: target-specific in, cytotoxics out?Drug Resistance Updates, 2004
- Mechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABLCell, 2003
- A Single Amino Acid Exchange Inverts Susceptibility of Related Receptor Tyrosine Kinases for the ATP Site Inhibitor STI-571Journal of Biological Chemistry, 2003
- Response to Imatinib Mesylate in Patients with Chronic Myeloproliferative Diseases with Rearrangements of the Platelet-Derived Growth Factor Receptor BetaNew England Journal of Medicine, 2002
- Glivec (STI571, imatinib), a rationally developed, targeted anticancer drugNature Reviews Drug Discovery, 2002